The amplification of tyrosinase mRNA by reverse transcription-PCR (RT-PCR) from peripheral blood has frequently been used as a marker for the presence of circulating tumor cells in melanoma patients (1 ) . Recently, tyrosinase mRNA was also demonstrated to be detectable in serum and plasma samples from melanoma patients, indicating that tumor-specific mRNA is present in an extracellular form in the bloodstream (2, 3 ) . This has been confirmed by other investigators demonstrating the presence of extracellular telomerase mRNA in the serum of breast cancer patients (4 ) . It has been speculated that the presence of tumor-associated mRNA in serum and plasma is possibly related to tumor cell necrosis and release of transcripts into the circulation. Furthermore, there is evidence to suggest that mRNA may be actively secreted by tumor cells in vivo (5, 6 ) . It is not yet clear, however, how serum and plasma mRNA is protected from RNases. Several findings have indicated that extracellular RNA might be protected from serum RNases by proteins or proteolipid complexes (6 -8 ) . Very recently, it was demonstrated that DNA and RNA are packaged separately into apoptotic bodies, producing two types of apoptotic bodies, one type containing RNA and no DNA and the other type containing DNA and no RNA (9 ) . This finding suggests that extracellular mRNA may circulate within apoptotic bodies, which may decrease their susceptibility to nucleases. The present study was therefore conducted to analyze the serum stability of tyrosinase mRNA associated with apoptotic bodies in comparison with free tyrosinase transcripts.
Cells (1 ϫ 10 6 cells/well) of the melanoma cell line Bu-Hom (established in our laboratory from a patient's lymph node metastasis) were plated in 6-well tissue culture plates (Costar) in 2 mL of medium consisting of Dulbecco's modified Eagle's medium containing 100 mL/L fetal serum and incubated at 37°C in 10% CO 2 . Cells were allowed to adhere overnight. Apoptosis of melanoma cells was induced by the addition of the agonistic cross-linking anti-CD95 monoclonal antibody 7C11 (50 g/L; Immunotech) for 48 h. At the termination of culture, cell-free supernatants were collected and passed through a 0.45 m filter.
Induction of apoptotic cell death and apoptotic bodies was confirmed by different methods. In the first method, melanoma cells were precisely analyzed by light microscopy, and morphologic changes characterizing apoptotic cell death were identified. In the second method, apoptotic bodies present in collected cell-free supernatants were identified by double staining and subsequent flow cytometry using fluorescein isothiocyanate-labeled annexin V, a marker for early and late apoptosis, and propidium iodide, a marker for late apoptosis and necrosis (TACS Annexin V Apoptosis Detection reagent set; Genzyme). These studies confirmed the presence of apoptotic bodies in culture supernatants of melanoma cells incubated with monoclonal antibody 7C11. In the third method, apoptotic bodies present in supernatants were attached to microscope slides, fixed in ice-cold solution containing 10 g/L methanol-free formaldehyde in phosphate-buffered saline for 15 min, and postfixed in cold 700 mL/L ethanol for at least 2 h. The presence of RNA in apoptotic bodies was confirmed by staining with pyronin Y (20 mg/L; Sigma). Fluorescence microscopy (570 nm) identified typical granular structures representing apoptotic bodies that contained RNA.
Cell-free supernatant (1 mL) from 1 ϫ 10 6 cultured melanoma cells was mixed with 2 mL of fresh serum from controls and incubated at 37°C for different periods of time. As a control, 1 g of free total RNA isolated from Bu-Hom melanoma cells was mixed with normal serum. After the indicated time points, serum samples were stabilized with RNA/DNA Stabilization Reagent for Blood/Bone Marrow (Roche Diagnostics). Poly(A) ϩ mRNA was extracted using the mRNA Isolation Kit for Blood and Bone Marrow (Roche Diagnostics) according to the manufacturer's protocol. cDNA was synthesized and amplified in a 50-L PCR reaction using the Qiagen One
Step RT-PCR reagent set (Qiagen). In brief, 6 L of mRNA was reverse-transcribed with specific primers for tyrosinase, using One Step RT-PCR enzyme mixture (Qiagen), and then amplified in the following PCR reaction using HotStarTaq DNA polymerase (Qiagen). The following tyrosinase primers were used in PCR reactions: 5Ј-TTG-GCAGATTGTCTGTAGCC-3Ј (sense) and 5Ј-AGGCATT-GTGCATGCTGCTT-3Ј (antisense). Cycling conditions were as follows: for reverse transcription of mRNA, 30 min at 50°C; for amplification of cDNA, an initial denaturation step of 15 min at 95°C, followed by 20 s of denaturation at 94°C, 20 s of annealing at 58°C, and 40 s of extension at 72°C. The PCR was cycled 60 times. PCR products were electrophoresed in a 1% agarose gel containing ethidium bromide and visualized under ultraviolet light.
We detected no tyrosinase-specific mRNA in serum samples mixed with free tumor cell-derived mRNA even when the mRNA was rapidly extracted 1 min after incubation. On the other hand, tyrosinase mRNA was amplifiable from serum samples mixed with cell-free supernatants containing apoptotic bodies from melanoma cells. Kinetic studies showed that tyrosinase mRNA associated with apoptotic bodies remained detectable by RT-PCR even after 30 min of incubation ( Fig. 1) . After an incubation period of 60 min, however, the apoptotic body mRNA was no longer amplifiable from these sera.
Our results confirm previous reports showing that when free RNA was added to blood, the RNA was nonamplifiable (10 ) . This finding is likely related to degradation by serum RNases present in human serum and plasma (11 ) . We now demonstrate, however, that tumor-derived mRNA associated with apoptotic bodies remains stable in serum. This indicates that RNA within apoptotic bodies is protected from degradation in serum even after prolonged exposure to nucleases. It is already known that tumor-derived DNA fragments frequently occur in the serum and plasma of cancer patients. Recent results suggest that a fraction of circulating tumor-specific DNA originates from apoptotic or necrotic cells (12 ) . In addition to DNA, tumor-specific RNA has been also found recently in serum and plasma samples from cancer patients. The present study indicates the possibility that apoptotic tumor cells are a source for plasma RNA that is protected from serum RNases within apoptotic bodies. Normal human serum (2 mL) was incubated for different periods of time with free mRNA (1 g; lanes 3 and 4), or with 1 mL of cell-free supernatants derived from 1 ϫ 10 6 apoptotic Bu-Hom melanoma cells (lanes 5-8). Lane 1, negative control (mRNA from Jurkat cells); lane 2, positive control (mRNA from Bu-Hom melanoma cells).
